Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.

Frontiers in neurology

Schindler SE, Fagan AM.
PMID: 26175713
Front Neurol. 2015 Jun 29;6:142. doi: 10.3389/fneur.2015.00142. eCollection 2015.

Our understanding of the pathogenesis of Alzheimer disease (AD) has been greatly influenced by investigation of rare families with autosomal dominant mutations that cause early onset AD. Mutations in the genes coding for amyloid precursor protein (APP), presenilin 1...

Cite
Schindler SE, Fagan AM. Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Front Neurol. 2015;6:142doi: 10.3389/fneur.2015.00142.
Schindler, S. E., & Fagan, A. M. (2015). Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Frontiers in neurology, 6142. https://doi.org/10.3389/fneur.2015.00142
Schindler, Suzanne Elizabeth, and Fagan, Anne M. "Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD." Frontiers in neurology vol. 6 (2015): 142. doi: https://doi.org/10.3389/fneur.2015.00142
Schindler SE, Fagan AM. Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD. Front Neurol. 2015 Jun 29;6:142. doi: 10.3389/fneur.2015.00142. eCollection 2015. PMID: 26175713; PMCID: PMC4483518.
Copy Download .nbib Format: NLM
Validity and power of minimization algorithm in longitudinal analysis of clinical trials.

Biostatistics & epidemiology

Weng H, Bateman R, Morris JC, Xiong C.
PMID: 29250611
Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13.

We studied the validity of longitudinal statistical inferences of clinical trials using minimization, a dynamic randomization algorithm designed to minimize treatment imbalance for prognostic factors. Repeated measures analysis of covariance and the random intercept and slope models, were used...

Cite
Weng H, Bateman R, Morris JC, et al. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77doi: 10.1080/24709360.2017.1331822.
Weng, H., Bateman, R., Morris, J. C., & Xiong, C. (2017). Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostatistics & epidemiology, 1(1), 59-77. https://doi.org/10.1080/24709360.2017.1331822
Weng, Hua, et al. "Validity and power of minimization algorithm in longitudinal analysis of clinical trials." Biostatistics & epidemiology vol. 1,1 (2017): 59-77. doi: https://doi.org/10.1080/24709360.2017.1331822
Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13. PMID: 29250611; PMCID: PMC5730087.
Copy Download .nbib Format: NLM
Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease.

Journal of proteome research

Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR.
PMID: 34818016
J Proteome Res. 2022 Jan 07;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24.

One of the potential benefits of using data-independent acquisition (DIA) proteomics protocols is that information not originally targeted by the study may be present and discovered by subsequent analysis. Herein, we reanalyzed DIA data originally recorded for global proteomic...

Cite
Hubbard EE, Heil LR, Merrihew GE, et al. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. J Proteome Res. 2021;21(1):118-131doi: 10.1021/acs.jproteome.1c00558.
Hubbard, E. E., Heil, L. R., Merrihew, G. E., Chhatwal, J. P., Farlow, M. R., McLean, C. A., Ghetti, B., Newell, K. L., Frosch, M. P., Bateman, R. J., Larson, E. B., Keene, C. D., Perrin, R. J., Montine, T. J., MacCoss, M. J., & Julian, R. R. (2022). Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. Journal of proteome research, 21(1), 118-131. https://doi.org/10.1021/acs.jproteome.1c00558
Hubbard, Evan E, et al. "Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease." Journal of proteome research vol. 21,1 (2022): 118-131. doi: https://doi.org/10.1021/acs.jproteome.1c00558
Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. J Proteome Res. 2022 Jan 07;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24. PMID: 34818016; PMCID: PMC8741752.
Copy Download .nbib Format: NLM
Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability.

Annals of clinical and translational neurology

Brier MR, Snyder AZ, Tanenbaum A, Rudick RA, Fisher E, Jones S, Shimony JS, Cross AH, Benzinger TLS, Naismith RT.
PMID: 33943045
Ann Clin Transl Neurol. 2021 May;8(5):1096-1109. doi: 10.1002/acn3.51354. Epub 2021 May 04.

OBJECTIVE: To enable use of clinical magnetic resonance images (MRIs) to quantify abnormalities in normal appearing (NA) white matter (WM) and gray matter (GM) in multiple sclerosis (MS) and to determine associations with MS-related disability. Identification of these abnormalities...

Cite
Brier MR, Snyder AZ, Tanenbaum A, et al. Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Ann Clin Transl Neurol. 2021;8(5):1096-1109doi: 10.1002/acn3.51354.
Brier, M. R., Snyder, A. Z., Tanenbaum, A., Rudick, R. A., Fisher, E., Jones, S., Shimony, J. S., Cross, A. H., Benzinger, T. L. S., & Naismith, R. T. (2021). Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Annals of clinical and translational neurology, 8(5), 1096-1109. https://doi.org/10.1002/acn3.51354
Brier, Matthew R, et al. "Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability." Annals of clinical and translational neurology vol. 8,5 (2021): 1096-1109. doi: https://doi.org/10.1002/acn3.51354
Brier MR, Snyder AZ, Tanenbaum A, Rudick RA, Fisher E, Jones S, Shimony JS, Cross AH, Benzinger TLS, Naismith RT. Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. Ann Clin Transl Neurol. 2021 May;8(5):1096-1109. doi: 10.1002/acn3.51354. Epub 2021 May 04. PMID: 33943045; PMCID: PMC8108425.
Copy Download .nbib Format: NLM
Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)

Aschenbrenner AJ, Petros J, McDade E, Wang G, Balota DA, Benzinger TL, Cruchaga C, Goate A, Xiong C, Perrin R, Fagan AM, Graff-Radford N, Ghetti B, Levin J, Weidinger E, Schofield P, Gräber S, Lee JH, Chhatwal JP, Morris JC, Bateman R, Hassenstab J.
PMID: 32587883
Alzheimers Dement (Amst). 2020 Jun 23;12(1):e12038. doi: 10.1002/dad2.12038. eCollection 2020.

INTRODUCTION: Changes in personality characteristics are associated with the onset of symptoms in Alzheimer's disease (AD) and may even precede clinical diagnosis. However, personality changes caused by disease progression can be difficult to separate from changes that occur with...

Cite
Aschenbrenner AJ, Petros J, McDade E, et al. Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimers Dement (Amst). 2020;12(1):e12038doi: 10.1002/dad2.12038.
Aschenbrenner, A. J., Petros, J., McDade, E., Wang, G., Balota, D. A., Benzinger, T. L., Cruchaga, C., Goate, A., Xiong, C., Perrin, R., Fagan, A. M., Graff-Radford, N., Ghetti, B., Levin, J., Weidinger, E., Schofield, P., Gräber, S., Lee, J. H., Chhatwal, J. P., Morris, J. C., Bateman, R., Hassenstab, J. (2020). Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands), 12(1), e12038. https://doi.org/10.1002/dad2.12038
Aschenbrenner, Andrew J, et al. "Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 12,1 (2020): e12038. doi: https://doi.org/10.1002/dad2.12038
Aschenbrenner AJ, Petros J, McDade E, Wang G, Balota DA, Benzinger TL, Cruchaga C, Goate A, Xiong C, Perrin R, Fagan AM, Graff-Radford N, Ghetti B, Levin J, Weidinger E, Schofield P, Gräber S, Lee JH, Chhatwal JP, Morris JC, Bateman R, Hassenstab J. Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimers Dement (Amst). 2020 Jun 23;12(1):e12038. doi: 10.1002/dad2.12038. eCollection 2020. PMID: 32587883; PMCID: PMC7311802.
Copy Download .nbib Format: NLM
Preclinical Alzheimer's disease and longitudinal driving decline.

Alzheimer's & dementia (New York, N. Y.)

Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC.
PMID: 28435853
Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006.

INTRODUCTION: Links between preclinical AD and driving difficulty onset would support the use of driving performance as an outcome in primary and secondary prevention trials among older adults (OAs). We examined whether AD biomarkers predicted the onset of driving...

Cite
Roe CM, Babulal GM, Head DM, et al. Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y). 2017;3(1):74-82doi: 10.1016/j.trci.2016.11.006.
Roe, C. M., Babulal, G. M., Head, D. M., Stout, S. H., Vernon, E. K., Ghoshal, N., Garland, B., Barco, P. P., Williams, M. M., Johnson, A., Fierberg, R., Fague, M. S., Xiong, C., Mormino, E., Grant, E. A., Holtzman, D. M., Benzinger, T. L. S., Fagan, A. M., Ott, B. R., Carr, D. B., & Morris, J. C. (2017). Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimer's & dementia (New York, N. Y.), 3(1), 74-82. https://doi.org/10.1016/j.trci.2016.11.006
Roe, Catherine M, et al. "Preclinical Alzheimer's disease and longitudinal driving decline." Alzheimer's & dementia (New York, N. Y.) vol. 3,1 (2017): 74-82. doi: https://doi.org/10.1016/j.trci.2016.11.006
Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC. Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006. PMID: 28435853; PMCID: PMC5396459.
Copy Download .nbib Format: NLM
Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters.

Journal of biopharmaceutical statistics

Liu J, Xiong C, Liu L, Wang G, Jingqin L, Gao F, Chen L, Li Y.
PMID: 32970522
J Biopharm Stat. 2021 Mar;31(2):191-206. doi: 10.1080/10543406.2020.1814795. Epub 2020 Sep 24.

To calculate sample sizes in cluster randomized trials (CRTs), the cluster sizes are usually assumed to be identical across all clusters for simplicity. However, equal cluster sizes are not guaranteed in practice, especially when the number of clusters is...

Cite
Liu J, Xiong C, Liu L, et al. Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters. J Biopharm Stat. 2020;31(2):191-206doi: 10.1080/10543406.2020.1814795.
Liu, J., Xiong, C., Liu, L., Wang, G., Jingqin, L., Gao, F., Chen, L., & Li, Y. (2021). Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters. Journal of biopharmaceutical statistics, 31(2), 191-206. https://doi.org/10.1080/10543406.2020.1814795
Liu, Jingxia, et al. "Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters." Journal of biopharmaceutical statistics vol. 31,2 (2021): 191-206. doi: https://doi.org/10.1080/10543406.2020.1814795
Liu J, Xiong C, Liu L, Wang G, Jingqin L, Gao F, Chen L, Li Y. Relative efficiency of equal versus unequal cluster sizes in cluster randomized trials with a small number of clusters. J Biopharm Stat. 2021 Mar;31(2):191-206. doi: 10.1080/10543406.2020.1814795. Epub 2020 Sep 24. PMID: 32970522.
Copy Download .nbib Format: NLM
Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease.

Journal of proteome research

Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR.
PMID: 34818016
J Proteome Res. 2022 Jan 07;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24.

One of the potential benefits of using data-independent acquisition (DIA) proteomics protocols is that information not originally targeted by the study may be present and discovered by subsequent analysis. Herein, we reanalyzed DIA data originally recorded for global proteomic...

Cite
Hubbard EE, Heil LR, Merrihew GE, et al. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. J Proteome Res. 2021;21(1):118-131doi: 10.1021/acs.jproteome.1c00558.
Hubbard, E. E., Heil, L. R., Merrihew, G. E., Chhatwal, J. P., Farlow, M. R., McLean, C. A., Ghetti, B., Newell, K. L., Frosch, M. P., Bateman, R. J., Larson, E. B., Keene, C. D., Perrin, R. J., Montine, T. J., MacCoss, M. J., & Julian, R. R. (2022). Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. Journal of proteome research, 21(1), 118-131. https://doi.org/10.1021/acs.jproteome.1c00558
Hubbard, Evan E, et al. "Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease." Journal of proteome research vol. 21,1 (2022): 118-131. doi: https://doi.org/10.1021/acs.jproteome.1c00558
Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. J Proteome Res. 2022 Jan 07;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24. PMID: 34818016; PMCID: PMC8741752.
Copy Download .nbib Format: NLM
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.

Clinical investigation

Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD.
PMID: 23139856
Clin Investig (Lond). 2012 Oct 01;2(10):975-984. doi: 10.4155/cli.12.93.

The Dominantly Inherited Alzheimer Network (DIAN) is a collaborative effort of international Alzheimer disease (AD) centers that are conducting a multifaceted prospective biomarker study in individuals at-risk for autosomal dominant AD (ADAD). DIAN collects comprehensive information and tissue in...

Cite
Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012;2(10):975-984doi: 10.4155/cli.12.93.
Morris, J. C., Aisen, P. S., Bateman, R. J., Benzinger, T. L., Cairns, N. J., Fagan, A. M., Ghetti, B., Goate, A. M., Holtzman, D. M., Klunk, W. E., McDade, E., Marcus, D. S., Martins, R. N., Masters, C. L., Mayeux, R., Oliver, A., Quaid, K., Ringman, J. M., Rossor, M. N., Salloway, S., Schofield, P. R., Selsor, N. J., Sperling, R. A., Weiner, M. W., Xiong, C., Moulder, K. L., & Buckles, V. D. (2012). Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clinical investigation, 2(10), 975-984. https://doi.org/10.4155/cli.12.93
Morris, John C, et al. "Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network." Clinical investigation vol. 2,10 (2012): 975-984. doi: https://doi.org/10.4155/cli.12.93
Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 01;2(10):975-984. doi: 10.4155/cli.12.93. PMID: 23139856; PMCID: PMC3489185.
Copy Download .nbib Format: NLM
Regional variability in Alzheimer's disease biomarkers.

Future neurology

Gordon BA, Blazey T, Benzinger TL.
PMID: 25309132
Future Neurol. 2014;9(2):131-134. doi: 10.2217/fnl.14.9.

No abstract available.

Cite
Gordon BA, Blazey T, Benzinger TL. Regional variability in Alzheimer's disease biomarkers. Future Neurol. 2014;9(2):131-134doi: 10.2217/fnl.14.9.
Gordon, B. A., Blazey, T., & Benzinger, T. L. (2014). Regional variability in Alzheimer's disease biomarkers. Future neurology, 9(2), 131-134. https://doi.org/10.2217/fnl.14.9
Gordon, Brian A, et al. "Regional variability in Alzheimer's disease biomarkers." Future neurology vol. 9,2 (2014): 131-134. doi: https://doi.org/10.2217/fnl.14.9
Gordon BA, Blazey T, Benzinger TL. Regional variability in Alzheimer's disease biomarkers. Future Neurol. 2014;9(2):131-134. doi: 10.2217/fnl.14.9. PMID: 25309132; PMCID: PMC4192718.
Copy Download .nbib Format: NLM
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

PloS one

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL.
PMID: 27649320
PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016.

[This corrects the article DOI: 10.1371/journal.pone.0152082.].

Cite
Su Y, Blazey TM, Owen CJ, et al. Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One. 2016;11(9):e0163669doi: 10.1371/journal.pone.0163669.
Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., Cash, L. A., Koeppe, R. A., Klunk, W. E., Galasko, D., Brickman, A. M., McDade, E., Ringman, J. M., Thompson, P. M., Saykin, A. J., Ghetti, B., Sperling, R. A., Johnson, K. A., Salloway, S. P., Schofield, P. R., Masters, C. L., Villemagne, V. L., Fox, N. C., Förster, S., Chen, K., Reiman, E. M., Xiong, C., Marcus, D. S., Weiner, M. W., Morris, J. C., Bateman, R. J., Benzinger, T. L. (2016). Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PloS one, 11(9), e0163669. https://doi.org/10.1371/journal.pone.0163669
Su, Yi, et al. "Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group." PloS one vol. 11,9 (2016): e0163669. doi: https://doi.org/10.1371/journal.pone.0163669
Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL. Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016. PMID: 27649320; PMCID: PMC5029931.
Copy Download .nbib Format: NLM
Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease.

Brain communications

Vermunt L, Dicks E, Wang G, Dincer A, Flores S, Keefe SJ, Berman SB, Cash DM, Chhatwal JP, Cruchaga C, Fox NC, Ghetti B, Graff-Radford NR, Hassenstab J, Karch CM, Laske C, Levin J, Masters CL, McDade E, Mori H, Morris JC, Noble JM, Perrin RJ, Schofield PR, Xiong C, Scheltens P, Visser PJ, Bateman RJ, Benzinger TLS, Tijms BM, Gordon BA.
PMID: 32954344
Brain Commun. 2020 Jul 15;2(2):fcaa102. doi: 10.1093/braincomms/fcaa102. eCollection 2020.

Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer's disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore,...

Cite
Vermunt L, Dicks E, Wang G, et al. Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Commun. 2020;2(2):fcaa102doi: 10.1093/braincomms/fcaa102.
Vermunt, L., Dicks, E., Wang, G., Dincer, A., Flores, S., Keefe, S. J., Berman, S. B., Cash, D. M., Chhatwal, J. P., Cruchaga, C., Fox, N. C., Ghetti, B., Graff-Radford, N. R., Hassenstab, J., Karch, C. M., Laske, C., Levin, J., Masters, C. L., McDade, E., Mori, H., Morris, J. C., Noble, J. M., Perrin, R. J., Schofield, P. R., Xiong, C., Scheltens, P., Visser, P. J., Bateman, R. J., Benzinger, T. L. S., Tijms, B. M., Gordon, B. A. (2020). Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain communications, 2(2), fcaa102. https://doi.org/10.1093/braincomms/fcaa102
Vermunt, Lisa, et al. "Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease." Brain communications vol. 2,2 (2020): fcaa102. doi: https://doi.org/10.1093/braincomms/fcaa102
Vermunt L, Dicks E, Wang G, Dincer A, Flores S, Keefe SJ, Berman SB, Cash DM, Chhatwal JP, Cruchaga C, Fox NC, Ghetti B, Graff-Radford NR, Hassenstab J, Karch CM, Laske C, Levin J, Masters CL, McDade E, Mori H, Morris JC, Noble JM, Perrin RJ, Schofield PR, Xiong C, Scheltens P, Visser PJ, Bateman RJ, Benzinger TLS, Tijms BM, Gordon BA. Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Commun. 2020 Jul 15;2(2):fcaa102. doi: 10.1093/braincomms/fcaa102. eCollection 2020. PMID: 32954344; PMCID: PMC7475695.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries